Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NOVAVAX INCNVAX · Entity 4632 | Director | December 24, 2024 | January 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NOVAVAX INC
Report date December 24, 2024 · Filed January 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,760 |
Ending reported balance
After 2024-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-12-24 · Sale · Disposed 4,600 · Balance 57,160 Row 2 · 2024-12-31 · Sale · Disposed 5,400 · Balance 51,760 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2019 Filed Dec 16, 2019 21:57 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to buy) · Derivative | 40,000 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001209191-19-060684 · doc4.xml · derivative · entry 1 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-12-12 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, will vest one (1) year from the December 12, 2019 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| December 12, 2019 Filed Mar 24, 2020 21:24 UTC Amendment | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to buy) · Derivative | 37,500 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001209191-20-020967 · doc4a.xml · derivative · entry 1 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2029-12-12 F1 · shares: The Reporting Person is amending the Form 4 originally filed solely to correct the number of stock options to purchase common stock of Novavax, Inc. (the "Company") acquired by the Reporting Person on December 12, 2019 under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "2015 Stock Plan"), and the related number of stock options beneficially owned following the reported transaction, due to an inadvertent error. F2 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Company's 2015 Stock Plan will vest one (1) year from the December 12, 2019 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 21:47 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to buy) · Derivative | 200,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001209191-18-062748 · doc4.xml · derivative · entry 1 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-12-13 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, will vest one (1) year from the December 13, 2018 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 21:10 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to buy) · Derivative | 200,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001209191-17-066312 · doc4.xml · derivative · entry 1 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-12-15 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, will vest one (1) year from the December 15, 2017 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 175,000 | $1.06 | $184,870.00 |
DisclosureSEC source: 0001209191-17-051058 · doc4.xml · nonDerivative · entry 1 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.05 to $1.075, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 20:13 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to buy) · Derivative | 200,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001209191-17-021703 · doc4.xml · derivative · entry 1 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-03-16 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan will vest one (1) year from the March 16, 2017 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:19 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 100,000 | $1.39 | $138,980.00 |
DisclosureSEC source: 0001209191-17-021088 · doc4.xml · nonDerivative · entry 1 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.395, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. F2 · balance_after: Since the date of the reporting person's last ownership report, he transferred 100,000 shares of Novavax common stock to his ex-wife pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.